J. Manro

发表

Developmental Expression of Human Hepatic CYP2C9 and CYP2C19

A. Rettie, S. B. Koukouritaki, J. Manro, 2004, Journal of Pharmacology and Experimental Therapeutics.

Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition

D. Alsop, P. Hipskind, Xiaoen Wang, 2019, Molecular Cancer Therapeutics.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

G. Plowman, Xiu-juan Yuan, B. Anderson, 2019, Molecular Cancer Therapeutics.

Cancer Therapy: Preclinical LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

Ying Tang, J. Manro, K. Credille, 2014 .

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

T. Doman, M. Kalos, J. Manro, 2022, PloS one.

Developmental Expression of Human Hepatic CYP 2 C 9 and CYP 2 C 19

A. Rettie, S. B. Koukouritaki, J. Manro, 2003 .

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Shobha N. Bhattachar, R. Campbell, Y. Qian, 2019, Molecular Cancer Therapeutics.

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1

T. Burke, R. Beckmann, J. Manro, 2018, Oncogene.

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

P. Iversen, M. Kalos, G. Plowman, 2018, Journal of Immunotherapy for Cancer.

ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer

C. Paweletz, P. Jänne, J. Köhler, 2021, Molecular Cancer Therapeutics.

Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

R. Walgren, J. Manro, J. Wijsman, 2013, Clinical Cancer Research.

Cancer Therapy : Preclinical Inhibition of Tumor Growth andMetastasis in Non – Small Cell Lung Cancer by LY 2801653 , an Inhibitor of Several Oncokinases , Including MET

R. Walgren, J. Manro, J. Wijsman, 2013 .

Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY 2801653 , an inhibitor of several oncokinases , including MET Authors

R. Walgren, J. Manro, J. Wijsman, 2013 .

Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma – Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3

T. Engler, K. Rank, J. Atkinson, 2015, PloS one.

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer

Xiu-juan Yuan, J. Manro, Sheng-Bin Peng, 2016, Oncotarget.

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Xiaohong Xu, Philip W. Iversen, David K. Clawson, 2017, Oncotarget.

Developmental Expression of the Major Human Hepatic CYP3A Enzymes

Ronald N. Hines, S. B. Koukouritaki, J. Manro, 2003, Journal of Pharmacology and Experimental Therapeutics.

In Vivo Assay Guidelines

S. Iturria, P. Iversen, Hui-Rong Qian, 2004 .

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

J. Graff, R. Walgren, C. Shih, 2012, Investigational New Drugs.

Cancer Therapy : Preclinical LY 2875358 , a Neutralizing and Internalizing Anti-MET Bivalent Antibody , Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

Ying Tang, J. Manro, K. Credille, 2014 .

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

T. Doman, E. Rasmussen, M. Kalos, 2019, Clinical Cancer Research.

LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

Ying Tang, J. Manro, K. Credille, 2014, Clinical Cancer Research.

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies

Xiufeng Wu, A. Sereno, F. Huang, 2021, Journal for ImmunoTherapy of Cancer.

Cancer Management and Research Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Patient-derived Acute Myeloid Leukemia (aml) Bone Marrow Cells Display Distinct Intracellular Kinase Phosphorylation Patterns

Michael Lahn, J. Manro, L. Green, 2022 .

Abstract 1236: Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)

Brian E. Mattioni, C. Mur, T. K. Baker, 2021, Experimental and Molecular Therapeutics.

Preclinical bridging studies: understanding dried blood spot and plasma exposure profiles.

J. Manro, K. Ruterbories, Naijia H Huang, 2013, Bioanalysis.

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

R. Walgren, J. Manro, V. Wacheck, 2017, Investigational New Drugs.

Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms

T. Doman, E. Rasmussen, M. Kalos, 2018, Clinical Research (Excluding Clinical Trials).

Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.

P. Hipskind, Hong Gao, J. Manro, 2013 .

Utility of Oatp1a/1b-Knockout and OATP1B1/3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution: Case Studies with Pravastatin, Atorvastatin, Simvastatin, and Carboxydichlorofluorescein

J. Manro, J. W. Higgins, A. Ke, 2014, Drug Metabolism and Disposition.

Utility of Oatp 1 a / 1 b-Knockout and OATP 1 B 1 / 3-Humanized Mice in the Study of OATP-Mediated Pharmacokinetics and Tissue Distribution : Case Studies with Pravastatin , Atorvastatin , Simvastatin , and Carboxydichlorofluorescein s

J. Manro, J. W. Higgins, A. Ke, 2013 .

Abstract 2734: c-Met antibody LY2875358 (LA480) shows differential antitumor effects in non-small cell lung cancer

Ying Tang, J. Manro, J. Lu, 2012 .

Pharmacological Characterization of cGMP Regulation by the Biarylpropylsulfonamide Class of Positive, Allosteric Modulators of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors

J. Manro, K. Merchant, K. Svensson, 2006, Journal of Pharmacology and Experimental Therapeutics.

How well do lipophilicity parameters, MEEKC microemulsion capacity factor, and plasma protein binding predict CNS tissue binding?

Thomas J. Raub, Stuart Morton, J. Manro, 2012, Journal of pharmaceutical sciences.

Abstract 4973: Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations

J. Manro, Sheng-Bin Peng, W. Mcmillen, 2017 .

Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns

J. Manro, L. Green, M. Lahn, 2009 .

Patient-derived acute myeloid leukemia (AML) bone marrow cells display distinct intracellular kinase phosphorylation patterns

J. Manro, L. Green, M. Lahn, 2009, Cancer Management and Research.

J. Manro, L. Green, M. Lahn, 2022 .

Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

R. Walgren, J. Manro, J. Wijsman, 2013, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

J. Manro, L. Green, M. Lahn, 2022 .